Mitochondrion as a novel target of anticancer chemotherapy

Journal of the National Cancer Institute

Volumn 92, Issue 13, 2000, Pages 1042-1053

  Costantini, Paola ^a   Jacotot, Etienne ^a   Decaudin, Didier ^b   Kroemer, Guido ^a,c  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 4' CHLORODIAZEPAM; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BENZODIAZEPINE RECEPTOR; BETULIC ACID; CYTOTOXIC AGENT; LIGAND; LONIDAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PROTEIN BCL 2;

ALPHA HELIX; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; DRUG TARGETING; HUMAN; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034608786     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.13.1042     Document Type: Review

References (143)

1. Apoptosis in the pathogenesis and treatment of disease
2. The biochemistry of programmed cell death
3. The central executioners of apoptosis: Caspases or mitochondria?
4. Mitochondria and apoptosis
5. BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases
6. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition
7. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak
8. PML induces a novel caspase-independent death process
9. Caspase-independent cell killing by Fas-associated protein with death domain
10. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death
11. Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers
12. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor
13. Apoptosis in hematopoietic cells (FL5.12) caused by interleukin-3 withdrawal: Relationship to caspase activity and the loss of glutathione
14. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells
15. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
16. Caspase-dependent activation of calpain during drug-induced apoptosis
17. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and - independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines
18. HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism
19. Mitochondrial control of nuclear apoptosis
20. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria
21. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
22. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease
23. The central executioner of apoptosis: Multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis
24. Molecular characterization of mitochondrial apoptosis-inducing factor
25. Mitochondrial release of caspases-2 and -9 during the apoptotic process
26. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
27. Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade
28. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
29. The release of cytochrome c from mitochondria: A primary site for Bcl- 2 regulation of apoptosis
30. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system
31. Reaper-induced apoptosis in a vertebrate system
32. Simultaneous release of adenylate kinase and cytochrome c in cell death
33. Mitochondrial diseases in mouse and man
34. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
35. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia
36. Movement of Bax from the cytosol to mitochondria during apoptosis
37. 2+ ions
38. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis
39. Bax directly induces release of cytochrome c from isolated mitochondria
40. The permeability transition pore complex: A target for apoptosis regulation by caspases and bcl-2-related proteins
41. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria
42. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis
43. Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore
44. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition
45. The mitochondrial permeability transition pore and its role in cell death
46. 2+
47. Reconstituted adenine nucleotide translocase forms a channel for small molecules comparable to the mitochondrial permeability transition pore
48. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator
49. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC
50. Isolation of the mitochondrial benzodiazepine receptor: Association with the voltage-dependent anion channel and the adenine nucleotide carrier
51. Complexes between kinases, mitochondrial porin and adenylate translocator in rat brain resemble the permeability transition pore
52. The role of creatine kinase in inhibition of mitochondrial permeability transition
53. The mitochondrial permeability transition
54. The thiol crosslinking agent diamide overcomes the apoptosis- inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition
55. Subcellular and submitochondrial mode of action of Bcl-like oncoproteins
56. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore
57. Purification and liposomal reconstitution of the permeability transition pore complex
58. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore
59. Investigation of bax-induced release of cytochrome c from yeast mitochondria. Permeability of mitochondrial membranes, role of VDAC and ATP requirement
60. Expression of human ANT2 gene in highly proliferative cells: GRBOX, a new transcriptional element, is involved in the regulation of glycloytic ATP import into mitochondria
61. Characterization of a silencer element and purification of a silencer protein that negatively regulates the human adenine nucleotide translocator 2 promoter
62. Up-regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma
63. Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer
64. The beneficial effect of phosphocreatine accumulation in the creatine kinase transgenic mouse liver in endotoxin-induced hepatic cell death
65. Cloning and characterization of PRAX-1. A new protein that specifically interacts with the peripheral benzodiazepin receptor
66. Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage
67. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
68. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas
69. BAX frameshift mutations in cell lines derived from human hematopoietic malignancies are associated with resistance to apoptosis and microsatellite instability
70. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium
71. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX
72. Bcl-2 and the regulation of programmed cell death
73. Molecular thanatopsis: A discourse on the BCL2 family and cell death
74. The proto-oncogene Bcl-2 and its rote in regulating apoptosis
75. Double identity for proteins of the Bcl-2 family
76. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis
77. Oncogenic alterations of metabolism
78. Hexokinase type II: A novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells
79. Hexokinase receptors: Preferential enzyme binding in normal cells to nonmitochondrial sites and in transformed cells to mitochondrial sites
80. The mitochondrial death/life regulator in apoptosis and necrosis
81. Molecular ordering of apoptosis induced by anticancer drags in neuroblastoma cells
82. A model for p53-induced apoptosis
83. Implication of mitochondrial hydrogen peroxide generation in ceramide- induced apoptosis
84. The permeability transition pore as a mitochondrial calcium release channel: A critical appraisal
85. The permeability transition pore. Control points of a cyclosporin A- sensitive mitochondrial channel involved in cell death
86. Alterations to glutathione and nicotinamide nucleotides during the mitochondrial permeability transition induced by peroxynitrite
87. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition
88. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites
89. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis
90. The ADP-ATP translocation in mitochondria, a membrane potential controlled transport
91. Regulation of ceramide production and apoptosis
92. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death
93. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis
94. Commitment to apoptosis by GD3 ganglioside depends on opening of the mitochondrial permeability transition pore
95. Palmitate induces apoptosis via a direct effect on mitochondria
96. 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition
97. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria
98. Regulated targeting of BAX to mitochondria
99. The pro-apoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex
100. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
101. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X
102. Deletion of the loop region of Bcl-2 completely blocks paclitaxel- induced apoptosis
103. Microtubule-active drags suppress the closure of the permeability transition pore in tumour mitochondria
104. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c
105. Two CD95 (APO-1/Fas) signaling pathways
106. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
107. Mitochondrial membrane potential in living cells
108. Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077
109. Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077
110. Chloromethyl-X-rosamine (MitoTracker Red) photosensitizes mitochondria and induces apoptosis in intact human cells
111. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial
112. Cisplatin, epirubicin, and lonidamine combination regimen as first- line chemotherapy for metastatic breast cancer: A pilot study
113. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial
114. bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in Adriamycin-resistant MCF7 cells
115. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
116. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed ceils
117. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and plasma cells from myeloma patients
118. Apoptosis and growth inhibition in malignant lymphocytes alter treatment with arsenic trioxide at clinically achievable concentrations
119. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro and causes growth inhibition in xenografts in vivo
120. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells
121. Bcl-XL(L) expression and its downregulation by a novel retinoid in breast carcinoma cells
122. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway
123. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus
124. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid
125. An inducible recombinant adenoviral vector encoding Bax selectively induces apoptosis in ovarian cancer cells
126. A binary adenoviral vector system for expressing high levels of the pro-apoptotic gene bax
127. The peptide mastoparan is a potent facilitator of the mitochondrial permeability transition
128. Establishment of a cell-free system of neuronal apoptosis: Comparison of premitochondrial, mitochondrial, and postmitochondrial phases
129. Anti-cancer activity of targeted pro-apoptotic peptides
130. NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: Molecular insights into its biological functions
131. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore
132. Mitochondrial targeting of the p1311 protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-1)
133. Interleukin 2-Bax: A novel prototype of human chimeric proteins for targeted therapy
134. Mitochondrial permeability transition triggers lymphocyte apoptosis
135. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection
136. Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrin-derived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity
137. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment
138. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
139. Lonidamine induces apoptosis in drag-resistant cells independently of the p53 gene
140. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase- dependent, p53-independent pathway
141. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors
142. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells